<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210688</url>
  </required_header>
  <id_info>
    <org_study_id>ADAPT in MCN</org_study_id>
    <nct_id>NCT03210688</nct_id>
  </id_info>
  <brief_title>Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy</brief_title>
  <acronym>ADAPTinMCN</acronym>
  <official_title>Treatment of Primary Minimal Change Nephropathy: A Randomized Open-labeled Non-inferiority Study on Prednisolone and Vitamin D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traditionally MCN is treated with a high dose of prednisolone, which induces remission in
      60-90% of patients. Prednisolone treatment contains numerous side effects and the current
      dose is empiric. Given the lack of efficacy evidence and the risk associated with the
      currently accepted treatment regimen there is a need to characterize the outcome in MCN
      further, and to establish new, and potentially less toxic treatment regimens.

      The aim is to examine if treatment with reduced dose of prednisolone in combination with
      activated vitamin D is as effective as standard high dose prednisolone in achieving remission
      and preventing relapse in MCN, and if reduced dose prednisolone is associated with fewer side
      effects compared to standard dose. Furthermore, the study will examine the influence of
      prednisolone metabolism on the efficacy and side effects of prednisolone in the treatment of
      MCN.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission</measure>
    <time_frame>4 to 16 weeks</time_frame>
    <description>Time from treatment to remission and the frequency of patients reaching remission on treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>4 weeks to 1 year after remission</time_frame>
    <description>Frequency of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects to treatment</measure>
    <time_frame>4 weeks to 1 year after remission</time_frame>
    <description>The side effects to prednisolone are assessed using questionnaires by both patients and doctors, including SF36 and Cushing QoL. The Glucocorticoid Toxicity Index will be used to quantitate prednisolone-related morbidity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Minimal Change Disease</condition>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>High dose prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisolone 1 mg/kg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alfacalcidol and low dose prednisolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alfacalcidol 0,5 microgram/day and Prednisolone 0,5 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Tablet prednisolone</description>
    <arm_group_label>High dose prednisolone</arm_group_label>
    <arm_group_label>Alfacalcidol and low dose prednisolone</arm_group_label>
    <other_name>Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfacalcidol</intervention_name>
    <description>Capsule alfacalcidol 0,5 microgram/day</description>
    <arm_group_label>Alfacalcidol and low dose prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy proven minimal change nephropathy

          -  If earlier minimal change: No relapse in 5 years, and earlier only treated with
             prednisolone

          -  Nephrotic syndrome

          -  Age more than 18 years

        Exclusion Criteria:

          -  Cancer except from basal cells carcinoma

          -  Lymphoproliferative disease

          -  Pregnancy

          -  eGFR &lt; 30 ml/min/1,73m2 (CKD-EPI)

          -  Allergy

          -  No danish language

          -  No ability to give informed prove
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Ivarsen</last_name>
    <role>Study Chair</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tilde Kristensen, MD</last_name>
    <email>tilde.kristensen@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Per Ivarsen</last_name>
    <phone>+45 40460063</phone>
    <email>perivars@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Ivarsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Hospital Viborg</name>
      <address>
        <city>Viborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tilde Kristensen</last_name>
    </contact>
    <investigator>
      <last_name>Tilde Kristensen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prednisolone</keyword>
  <keyword>alfacalcidol</keyword>
  <keyword>Minimal change nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Nephrosis, Lipoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Alfacalcidol</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

